Authors: UNDERHILL C CLARKE K GREEN M MITCHELL P BARTLETT J BASSER R MAHER D CEBON J FINDLAY M DALLEY D BYRNE M CHER L GELDARD H SHIMOSAKA A BURGESS A KAYE A

Citation: C. Underhill et al., MX2 (KRN8602), AN ACTIVE NEW AGENT WITH LOW TOXICITY IN HIGH-GRADE MALIGNANT GLIOMA, Annals of oncology, 9, 1998, pp. 650-650

Authors: CLARKE K BASSER RL MAHER D MORGAN DJ CEBON J FOX RM HILL JS ALT C BARTLET J GELDARD H KAYE AH GREEN MD

Citation: K. Clarke et al., PHASE-I AND PHARMACOKINETIC STUDY OF KRN8602 ALONE AND WITH FILGRASTIM IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 16(6), 1998, pp. 2181-2187

Authors: MORGAN DJ HILL JS CLARKE K STYLLI SS PARK SJ CEBON J BASSER RL KAYE AH GELDARD H MAHER DW GREEN MD

Citation: Dj. Morgan et al., EFFECT OF FILGRASTIM ON THE PHARMACOKINETICS OF MX2 HYDROCHLORIDE IN PATIENTS WITH ADVANCED MALIGNANT DISEASE, Cancer chemotherapy and pharmacology, 41(5), 1998, pp. 423-426

Authors: MORGAN DJ HILL JS CLARKE K STYLLI SS PARK SJ CEBON J BASSER RL KAYE AH GELDARD H MAHER DW GREEN MD

Citation: Dj. Morgan et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF MX2 HYDROCHLORIDE IN PATIENTS WITH ADVANCED MALIGNANT DISEASE, Cancer chemotherapy and pharmacology, 40(3), 1997, pp. 202-208